NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis by Hausmann, M et al.
University of Zurich





NAT1 genotypes do not predict response to mesalamine in
patients with ulcerative colitis
Hausmann, M; Paul, G; Menzel, K; Brunner-Ploss, R; Falk, W; Schölmerich, J;
Herfarth, H; Rogler, G
Hausmann, M; Paul, G; Menzel, K; Brunner-Ploss, R; Falk, W; Schölmerich, J; Herfarth, H; Rogler, G (2008).




Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Zeitschrift für Gastroenterologie 2008, 46(3):259-265.
Hausmann, M; Paul, G; Menzel, K; Brunner-Ploss, R; Falk, W; Schölmerich, J; Herfarth, H; Rogler, G (2008).




Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Zeitschrift für Gastroenterologie 2008, 46(3):259-265.
NAT1 genotypes do not predict response to mesalamine in
patients with ulcerative colitis
Abstract
BACKGROUND: 5- Aminosalicylic acid (5-ASA) is metabolised in colonic mucosa by
N-acetyltransferase 1 (NAT1). Common genetic polymorphisms in this enzyme result in rapid or slow
acetylation. 5-ASA treatment causes side effects in up to 10 % of patients with ulcerative colitis (UC).
We therefore determined genetic variations of NAT1 in patients with UC and looked for a possible
association with the clinical response to 5-ASA. METHODS: DNA was obtained from 78 patients with
UC. 77 % of the patients were in remission during 5-ASA treatment, whereas 23 % suffered from active
disease. NAT1 genotyping was performed for 23 known alleles using RFLP and sequence analysis.
Clinical response to 5-ASA was determined by medical record review and associated with NAT1
genotypes. RESULTS: Utilising PCR we amplified a 570-bp coding region of the human NAT1 gene in
addition to 240 bp in the 3'-untranslated region (UTR). 4 NAT1 alleles previously known as NAT1*3,
*4, *10 and *11 were recovered. 31 % of the patients were heterozygous and 4 % homozygous for the
NAT1*10 allele. 6 % were heterozygous for the NAT1*3 allele. 6 % were heterozygous for the
NAT1*11 allele. No association was found between NAT1 genotype and clinical response as well as
side effects to 5-ASA in patients with UC. CONCLUSIONS: NAT1 genotypes do not predict response
or side effects to mesalamine in patients with UC. Variations caused by non-genomic effects may be
associated with the clinical response to 5-ASA.
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Background: 5- Aminosalicylic acid (5-ASA) is metabolized in colonic mucosa by N-
acetyltransferase 1 (NAT1). Common genetic polymorphisms in this enzyme result in 
rapid and slow acetylation. 5-ASA treatment causes side effects in up to 10% of patients 
with ulcerative colitis (UC). We therefore determined genetic variations of NAT1 in 
patients with UC and a possible association with the clinical response to 5-ASA. 
Methods: DNA was obtained from 78 patients with UC. 77% of the patients were in 
remission during 5-ASA treatment, whereas 23% suffered from active disease. NAT1 
genotyping was performed for 23 known alleles using RFLP and sequence analysis. 
Clinical response to 5-ASA was determined by medical record review and associated 
with NAT1 genotypes. 
Results: Utilizing PCR we amplified a 570-bp coding region of the human NAT1 gene in 
addition to 240 bp in the 3´- untranslated region (UTR). 4 NAT1 alleles prior known as 
NAT1*3, *4, *10 and *11 were recovered. 31% of the patients were heterozygous and 
4% homozygous for the NAT1*10 allele. 6% were heterozygous for the NAT1*3 allele. 
6% were heterozygous for the NAT1*11 allele. No association was found between 
NAT1 genotype and clinical response as well as side effects to 5-ASA in patients with 
UC. 
Conclusions: NAT1 genotypes do not predict response or side effects to mesalamine 
in patients with UC. Variances caused by non-genomic effects may be associated with 
the clinical response to 5-ASA.




5-Aminosalicylate (5-ASA, mesalazine) is a therapeutically active agent during acute 
phase and remission maintenance treatment of UC [1]. Intestinal metabolite tissue 
levels of 5-ASA correlate with the therapeutic effect [2]. Efficacy of 5-ASA correlates 
with tissue delivery and, therefore, tissue delivery, intestinal metabolism and elimination 
may be important in determining drug efficacy [3]. 
 
5-ASA is metabolised by N-acetylation catalysed by N-acetyltransferases (NAT). Two 
isozymes NAT1 and NAT2 have been described in intestine [4][5] but NAT1 has been 
shown to be significantly more important for 5-ASA metabolism than NAT2 [6]. 
Expression of NAT1 and NAT2 mRNAs in humans is found in the whole gastrointestinal 
tract (esophagus, stomach, small intestine and colon) [5][7][8]. The specific NAT1 and 
NAT2 mRNAs were also present in small intestinal epithelial cells [9]. NAT1 activity is 
detected along the whole length of the [10]. 
 
It has been shown that intestinal metabolism of 5-ASA contributes to a greater extent to 
total body clearance than systemic N-acetylation of 5-ASA (as measured by urinary 
excretion) when the drug is administered as a delayed release dosage form 
[11][12][13][14].  
There is up to a 20-fold difference in acetylation rates of NAT1 substrates amongst 
different individuals [10][15][16][17][18][19]. NAT1 and NAT2 have been shown to differ 
significantly with respect to their intrinsic stability and their kinetic selectivity for amine-
containing acceptor substrates [5][20]. N-acetylation of 5-ASA by intestinal bacteria is 
minimal [21]. 
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NAT1 polymorphic enzymes [22][23][24], and thus individuals, segregate into rapid and 
slow acetylator phenotypes. The variation in the acetylation of NAT1-selective 
substrates has been shown to have a genetic basis [25]. For patients with ulcerative 
colitis (UC) it was suggested that NAT1 polymorphisms may have a role in the 
therapeutic response to 5-ASA and for side effects [26]. It was speculated that intestinal 
NAT-1 activity may correlate with efficacy of 5-ASA treatment and could be important in 
determining drug efficacy before therapy. In a previous phenotype study by Ricart et. al. 
[27] no significant association between the clinical response to mesalamine and the 
NAT1 acetylator status univariately or adjusted for dose or duration of therapy was 
found. However, the NAT1 acetylator status has not been associated with adverse 
effects related to the therapy. This led us to investigate known allelic variants of NAT1 in 
78 UC patients and to correlate it with 5-ASA induced side effects and the therapeutic 
response to 5-ASA treatment. 
To date 26 allelic variants of NAT1 have been reported 
(http://www.louisville.edu/medschool/pharmacology/NAT.html). Allelic variants of NAT1 
found in this study are listed in table 1. A map showing all described nucleotide 
substitutions proved is given in figure 1. NAT1*4 is the most common allele and was 
classified as wild-type. The NAT1*10 allele has been associated with rapid acetylator 
phenotype both in vitro [7][25] and in vivo [25][28]. NAT1*10 was mentioned to exhibit 
altered functional capacity [7][25]. The NAT1*11 allele has been associated with slow 
acetylator phenotype with low levels of activity [29]. 
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Material and methods 
 
Patients and DNA-isolation  
Blood samples were obtained from 78 patients with UC from the German IBD 
competence network serum bank (Core facility Regensburg, table 2). The study was 
approved by the University of Regensburg Ethics Committee. Genomic DNA was 
purified from human whole blood samples with the QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer´s protocol. Briefly, DNA was 
isolated following cell lysis and proteinase K digestion (56°C, 10 min). DNA was loaded 
on a QIAamp spin column, washed twice and eluted in 200 μl distilled water. 
Medication of 78 patients UC: all patients (100%) received 5-ASA p.o. (median dose 3.0 
g/day, range 1.0 – 8.0 g/day, median duration of treatment 365 days, range 1380 - 30 
days). Glucocorticosteroids were given to 56% of the UC patients and 26% of the 
patients received a 6-mercaptopurine therapy. 
 
 
Polymerase chain reaction (PCR) 
Amplifications of NAT1 DNA fragments by PCR were performed according to a 
modification of a method previously described [30]. Briefly, for the initial NAT1 PCR 150 
ng of genomic DNA, 150 ng of upstream primer (described in [30]), 90 ng of 
downstream primer were mixed in a 30 μl reaction with 15 μl master mix (Taq PCR 
Master Mix Kit, Qiagen, Hilden, Germany). After pretreatment at 94°C for 5 min the 
PCR for NAT1 comprised 30 cycles with denaturing at 94°C for 1 min, annealing at 
55°C for 1 min, extension at 72°C for 1 min and concluded with a extension step at 
72°C for 7 min in a TRIO-Thermoblock (Biometra, Goettingen, Germany). 
Hausmann et al. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis 
____________________________________________________________________________________________ 
7
For the detection of C559T, G560A and T1088A nucleotide changes nested PCRs with 0.5 
μl NAT1 PCR product were performed in a 20 μl reaction with 200 ng of appropriate 
primers [30] as described above. C1095A was detected in a 35 μl reaction. 
 
 
Restriction fragment length polymorphismus (RFLP) analysis 
RFLP analysis was realized according to a method previously described [30]. In brief, to 
confirm NAT1 amplification or to analyse the nucleotide substitution G350,351C 10 μl of 
the NAT1 PCR product were mixed in a 20 μl reaction including 10 units AatII or BanI 
(New England BioLabs, Frankfurt, Germany), respectively in the recommended buffer at 
37°C for 14 hours. 
To analyse the nucleotide substitution C1095A 20 μl of the according nested PCR 
product were mixed in a 35 μl reaction including 5 units Alw26I (MBI Fermentas, St. 
Leon-Rot, Germany) in the recommended buffer at 37°C for 14 hours. 
To distinguish nucleotide substitutions C559T, G560A and T1088A 17 μl of the according 
nested PCR product were mixed in a 20 μl reaction including 5 units of ScaI, HinfI or 
AseI (each New England BioLabs), respectively in the recommended buffer at 37°C for 
14 hours. 
Digested samples were size fractionated on a 1,2% E-gel® gel (Invitrogen, Leek, 
Netherlands) and visualized and photographed under ultraviolet light. 
To detect an insertion or deletion between nucleotide 1089 and 1091 or 1065 and 1090, 
repectively, 30 μl of the C1095 nested PCR product were mixed in a 50 μl reaction 
including 2 units of MseI (New England BioLabs) in the recommended buffer at 37°C for 
14 hours. Digested samples were size fractionated on a 5% Metaphor gel (FMC 
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BioProducts, Rockland ME) containing ethidium bromide and then visualized and 
photographed under ultraviolet light. 
 
 
DNA Sequence analysis 
Results from RFLP analysis were confirmed by sequence analysis. 150 ng of genomic 
DNA, 140 ng of upstream primer 5´ ATC TCC TAG AAG ACA GCA AAT AC 3´, 140 ng 
of downstream primer downstream primer 5´ GCT TTC TAG CAT AAA TCA CCA A 
3´were mixed in a 50 μl reaction including 5 μl dNTP (10 μM each, BD Biosciences 
Clontech, Heidelberg, Germany) and 1 μl Advantage™-HF2 Polymerase Mix (BD 
Biosciences Clontech, Heidelberg, Germany) in the recommended buffer. After 
pretreatment at 94°C for 2 min the PCR comprised 30 cycles with denaturing at 94°C 
for 30 seconds, annealing at 60°C for 30 seconds, extension at 68°C for 30 seconds 
and concluded with a extension step at 68°C for 7 min. The reactions were performed in 
a TRIO-Thermoblock (Biometra, Goettingen, Germany). PCR products were purified 
with the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany), sequenced and 
proved for heterozygous and homozygous mutations. 
 
Statistical analysis 
Expected gene frequencies were calculated from four respective single allele 
frequencies determined according to the Hardy-Weinberg equation for four alleles [(p + 
q + r + s)2 = 1; where p, q, r and s = allele frequency]. 
 






We amplified a 1158-bp NAT1 PCR product containing 278 bp in the 3´-UTR. AatII 
digestion confirmed NAT1 amplification (figure 2A). NAT1 genotyping was performed for 
23 alleles (NAT1*3, 4, 5, 10, 11A/B/C, 14A/B, 15, 16, 18A/B, 21, 22, 23, 24, 25, 26A/B, 27, 28 
and 29) using RFLP analysis and DNA sequencing. 
The nucleotide substitution G350,351C (according to a mutation occurring in the NAT1*5 
allele) was determined by BanI digests of the 1158-bp NAT1 PCR product. Gel 
electrophoresis revealed a 713 and 445 bp band in all analyzed samples (figure 2B) 
indicating that G350,351C substitutions were not present in any of the patients. 
The substitution C559T (allele NAT1*15) was determined by ScaI digests of the 
appropriate NAT1 nested PCR product. A single 138 bp band in all analyzed samples 
(figure 2C) indicated that no C559T substitutions were present. 
The substitution G560A (NAT1*14) was determined by HinfI digests of the appropriate 
NAT1 nested PCR product. 146, 90 and 25 bp bands in all analyzed samples (figure 
2D) indicated that no G560A substitutions were present. 
An insertion of a trinucleotide (AAA) (NAT1*16) and a deletion of 9 nucleotides (Δ9, 
NAT1*11) was determined by MseI digests of the appropriate NAT1 nested PCR 
product. Size fractionation on a 5% Metaphor gel revealed 62, 33, 25 and 12 bp bands 
in 71 samples indicating no mutation. In 5 samples evidence for a heterozygous 9-bp 
deletion was found indicated by bands with 62, 53, 33, 25 and 12 bp. Absence of AAA-
insertion and heterozygous 9-bp deletions were confirmed by DNA sequencing of all 
samples (figure 3). With the chosen test arrangement differentiation between NAT1*11A 
and NAT1*11C was not possible. NAT1*11B could be excluded. 
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The substitution T1088A (NAT1*10 and 14 allele) was determined by AseI digests of the 
appropriate NAT1 nested PCR product. 64 and 32 bp bands in 54 analyzed samples 
indicated no mutation. In 3 samples homozygous loss of the AseI site yielded in a single 
90 bp product. In 24 samples evidence for a heterozygous T1088A substitution was found 
indicated by bands with 90, 64 and 32 bp. Substitutions were confirmed by DNA 
sequencing of all samples (figure 3B and C). 
The substitution C1095A (according to a mutation occurring in the NAT1*3, 10, 11, 14 
and 16 allele) was determined by Alw26I digests of the appropriate NAT1 nested PCR 
product. 107 and 25 bp bands in 42 analyzed samples indicated no mutation. In 3 
samples homozygous loss of the Alw26I site yielded in a single 132 bp product. In 33 
samples evidence for a heterozygous C1095A substitution was found indicated by bands 
with 132, 107 and 25 bp. Substitutions were confirmed by DNA sequencing of all 
samples (figure 3B and C). 
NAT1 genotyping for the remaining alleles was performed using DNA sequencing only. 
No NAT1*18A/B, 21, 22, 23, 24, 25, 26A/B, 27, 28 or 29 alleles were present (table 3 and 
4). 




Overall, 16 of 78 patients (21%) treated with mesalazine experienced toxicity related to 
the therapy with symptoms severe enough to discontinue mesalazine (table 5 and 6). 
The observed adverse events were as follows: nausea (3 patients), elevated liver 
enzymes (3 patients), stomach pain (3 patients), headache (2 patients), heartpain (2 
patients), hemolysis (2 patients) and arthralgia (one patient). In all, 16 of 73 (22%) 
NAT1 rapid acetylator patients experienced toxicity to mesalazine (table 7). None of 5 
slow acetylator patients experienced toxicity to mesalazine.  
Patients with rapid and slow acetylator phenotype did not differ significantly with respect 
to dose (p = 0.18, table 7), duration of therapy (p = 0.83), remission time (p = 0.80), age 
at initial diagnosis (p = 0.29), time after initial diagnosis (p = 0.73) and bowel 
movements (p = 0.56).  
Patients experiencing toxicity to mesalazine and patients continuing mesalazine 
treatment did also not differ significantly with respect to duration of therapy (p = 0.89), 
remission period (p = 0.13), age at initial diagnosis (p = 0.80), time after initial diagnosis 
(p = 0.13) and bowel movements (p = 0.20). Multifactorial analysis with respect to 5-
ASA medication was not intended due to major dose range between 1.0 – 8.0 g/day and 
undersized representing patient numbers. 
 




In the present study we investigated allelic variants of NAT1 in UC patients treated with 
mesalamine. Confirming earlier data we found no relationship between the NAT1 
genotype and the clinical response to mesalamine [27][31]. Interestingly, none of the 
UC patients with a slow acetylator phenotype experienced toxicity related to the therapy 
with symptoms severe enough to discontinue mesalazine.  
The classification of patients with NAT1 polymorphisms into rapid and slow acetylator 
phenotypes is discussed controversially. The NAT1*10 allele has been associated with 
rapid acetylator phenotype both in vitro [7][25] and in vivo [25][28]. But recombinant 
expression studies have failed to confirm this conclusion [32]. Others confirmed the 
absence of functional consequences of enzyme activity in carriers of NAT1*10 allele 
[17]. The NAT1*11 allele has been associated with slow acetylator phenotype [33] and 
with low level of activity [29]. However, NAT1*11 was also classified as potential high 
activity allele [33]. In our study acetylator phenotypes were classified according to Bruhn 
et. al. [17]. Here the N-acetylation velocity was stratified for different genotypes of NAT1 
by an assay quantifying the formation of N-acetyl-para-acetamidobenzoic acid by a 
HPLC method. 
In a previous study by Ricart et. al. [27] NAT1 genotypes from 77 white patients of both 
sexes were determined. In both studies the observed frequencies of NAT1 were similar 
for *3/*4 (3 vs 5%), *3/*11 (0 vs 1%), *4/*4 (56 vs 54%), *4/*10 (25 vs 31%), *4/*11 (5 vs 
5%), *10/*10 (5 vs 4%). However, we did not find the NAT1*3/*14A and *3/*18 allele in 
our patients. No association of the clinical response to mesalamine with NAT1 rapid 
versus slow acetylator status was found confirming the data of Ricart and coworkers 
[27].  
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Further, we found that UC patients with a slow acetylator phenotype (NAT1*3/*11 and 
NAT1*4/*11) experienced no toxicity related to the therapy with symptoms severe 
enough to discontinue mesalazine. In contrast 20% of the UC patients with normal or 
rapid acetylator phenotype discontinued mesalazine due to 5-ASA intolerance. The side 
effects documented during treatment of the UC patients included in this study were as 
expected from the unwanted effects described in the literature: mainly stomach pain 
(mild or severe); headache (mild or severe) and nausea. No case of mesalazine-
induced acute renal dysfunction or failure was documented.  
Consistent with previous data from other groups our data indicate that NAT1 genotypes 
do not predict response to mesalamine in patients with UC. However, UC patients with 
a slow acetylator phenotype may be less affected from toxicity to mesalamine. Variation 
in the acetylation of NAT1-selective substrates may have a non-genetic or 
environmental basis not provable with the provided study design. 





This work was supported by the Wilhelm - Sander foundation, the DFG (SFB 585, 
project A6) and the BMBF IBD Network of Competence (Kompetenznetz – CED). 
 




Table 1: Prior known allelic variants of NAT1 recovered in this study. NAT1*11 includes 
additional nucleotide substitutions not shown. 
 
Table 2: Characteristics of patients. 
 
Table 3: NAT1 mutations determined in 78 patients and designation to NAT1 
haplotypes. The chosen test did not allow differentiation between NAT1*11A and 
NAT1*11C arrangement. 
 
Table 4: Observed frequency distribution of NAT1 genotypes among 78 patients. 
Expected frequencies are calculated from the allelic frequencies (table 3) by the Hardy-
Weinberg law. 
 
Table 5: Association between NAT1 alleles and side effects, remission status or bowel 
movements. 
 
Table 6: Association between NAT1 genotypes and side effects, remission status or 
bowel movements. 
 
Table 7: Association between different acetylator phenotypes. None of the UC patients 
with slow acetylator phenotype showed 5-ASA intolerance. 
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Figure 1: Nucleotide substitutions proven in this study. Δ: deletion, ins: insertion, black 
line: 3´ and 5´ untranslated region, box: coding sequence. According to Cascorbi et al. 
[34]. 
Figure 2: Gel electrophoresis following restriction enzyme digests on the 1158-bp NAT1 
PCR and the appropriate nested PCR products. (A) Molecular weight marker 100 bp 
DNA ladder (M) and AatII digestion (lane 1-5). 1158-bp confirmed correct NAT1 
amplification. (B) Molecular weight marker φX174/HaeIIIφ (Promega) and BanI digestion 
(lane 1-5). 713 and 445 bp indicated no G350,351C substitution. (C) 1007-bp undigested 
positive control (lane 1). ScaI digestion. 762 and 245-bp digested positive control 
demonstrated enzyme viability (lane 2 and 3). 138 bp indicated no C559T substitution 
(lane 4-6). (D) HinfI digestion. 146, 90 and 25 bp indicated no G560A substitution (lane1-
5). 
 
Figure 3: Position 1085–1099 of the sequenced 1158-bp NAT1 PCR product. (A) wt, 
(B) homozygous sustitutions T1088A (*) and C1095A (**), (C) heterozygous sustitutions 
T1088A (*) and C1095A (**), (D) heterozygous sustitution C1095A (**) and heterozygous 9 
bp deletion (#). 
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